On Wednesday, the first of a new type of cancer-fighting cell therapy called CAR-T was approved in the U.S.: Novartis AG’s Kymriah, intended to treat young people with acute lymphoblastic leukemia.
The science behind Kymriah and other CAR-T therapies is radical, even revolutionary, experts say: a patient’s immune T-cells are taken from the body, re-engineered to better fight cancer and then replaced in the body to do just that.
